Cargando…

Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: A systematic review and meta-analysis

BACKGROUND: Patients with cancer are of a high level risk of venous thromboembolism (VTE). Low molecular weight heparin (LMWH) is recommended as the normal treatment for cancer-associated venous thrombosis. Recently, some studies suggest that patients with cancer-associated venous thrombosis can get...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hailong, Tao, Rui, Zhao, Hui, Jiang, Jianjun, Yang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004711/
https://www.ncbi.nlm.nih.gov/pubmed/32000440
http://dx.doi.org/10.1097/MD.0000000000019000
_version_ 1783494785069219840
author Chen, Hailong
Tao, Rui
Zhao, Hui
Jiang, Jianjun
Yang, Jin
author_facet Chen, Hailong
Tao, Rui
Zhao, Hui
Jiang, Jianjun
Yang, Jin
author_sort Chen, Hailong
collection PubMed
description BACKGROUND: Patients with cancer are of a high level risk of venous thromboembolism (VTE). Low molecular weight heparin (LMWH) is recommended as the normal treatment for cancer-associated venous thrombosis. Recently, some studies suggest that patients with cancer-associated venous thrombosis can get a good efficacy and safety profile from treating with direct oral anticoagulants (DOACs) compared with other anticoagulants. However, when it comes to the efficacy of DAOCs in preventing VTE in patient with cancer, the data are limited. Thus, we performed such a meta-analysis to determine the efficacy and safety of DOACs in preventing VTE in patient with cancer compared with LMWHs. METHODS: Medline/PubMed and CENTRAL (The Cochrane Central Register of Controlled Trials) were systematically searched for relevant studies. For each trial, data on VTE, major bleeding, or bleeding were extracted by 2 reviewers independently. Pooled risk ratios (RRs) were calculated by using Review Manager 5.3 software and the significance was determined by the Z test. RESULTS: A total of 6 studies with 7185 patients were included in our meta-analysis. DOACs (RR = 0.55, 95% confidence interval [95%CI]: 0.34–0.90, I(2) = 31%) had a similar prevention effect of VTE to LMWH (RR = 0.59, 95% CI: 0.37–0.95, I(2) = 59%). DOACs (RR = 1.52, 95% CI: 0.99–2.33, I(2) = 0%) yielded a similar bleeding occurrence rate compared with LMWH (RR = 1.35, 95% CI: 1.07–1.70, I(2) = 35%). DOACs (RR = 1.95, 95% CI: 0.88–4.30, I(2) = 0%) showed a sight higher major bleeding occurrence rate than LMWH (RR = 1.38, 95% CI: 0.88–2.14, I(2) = 0%). CONCLUSION: DOACs show comparable efficacy to LMWH in cancer patients without VTE with a slightly higher major bleeding occurrence rate. DOACs are inclined to be an alternative thromboprophylaxis strategy in cancer patients as they have superiorities compared to traditional anticoagulation agents. Further studies are still demanded as exiting relevant researches are limited.
format Online
Article
Text
id pubmed-7004711
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-70047112020-02-18 Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: A systematic review and meta-analysis Chen, Hailong Tao, Rui Zhao, Hui Jiang, Jianjun Yang, Jin Medicine (Baltimore) 3400 BACKGROUND: Patients with cancer are of a high level risk of venous thromboembolism (VTE). Low molecular weight heparin (LMWH) is recommended as the normal treatment for cancer-associated venous thrombosis. Recently, some studies suggest that patients with cancer-associated venous thrombosis can get a good efficacy and safety profile from treating with direct oral anticoagulants (DOACs) compared with other anticoagulants. However, when it comes to the efficacy of DAOCs in preventing VTE in patient with cancer, the data are limited. Thus, we performed such a meta-analysis to determine the efficacy and safety of DOACs in preventing VTE in patient with cancer compared with LMWHs. METHODS: Medline/PubMed and CENTRAL (The Cochrane Central Register of Controlled Trials) were systematically searched for relevant studies. For each trial, data on VTE, major bleeding, or bleeding were extracted by 2 reviewers independently. Pooled risk ratios (RRs) were calculated by using Review Manager 5.3 software and the significance was determined by the Z test. RESULTS: A total of 6 studies with 7185 patients were included in our meta-analysis. DOACs (RR = 0.55, 95% confidence interval [95%CI]: 0.34–0.90, I(2) = 31%) had a similar prevention effect of VTE to LMWH (RR = 0.59, 95% CI: 0.37–0.95, I(2) = 59%). DOACs (RR = 1.52, 95% CI: 0.99–2.33, I(2) = 0%) yielded a similar bleeding occurrence rate compared with LMWH (RR = 1.35, 95% CI: 1.07–1.70, I(2) = 35%). DOACs (RR = 1.95, 95% CI: 0.88–4.30, I(2) = 0%) showed a sight higher major bleeding occurrence rate than LMWH (RR = 1.38, 95% CI: 0.88–2.14, I(2) = 0%). CONCLUSION: DOACs show comparable efficacy to LMWH in cancer patients without VTE with a slightly higher major bleeding occurrence rate. DOACs are inclined to be an alternative thromboprophylaxis strategy in cancer patients as they have superiorities compared to traditional anticoagulation agents. Further studies are still demanded as exiting relevant researches are limited. Wolters Kluwer Health 2020-01-31 /pmc/articles/PMC7004711/ /pubmed/32000440 http://dx.doi.org/10.1097/MD.0000000000019000 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 3400
Chen, Hailong
Tao, Rui
Zhao, Hui
Jiang, Jianjun
Yang, Jin
Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: A systematic review and meta-analysis
title Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: A systematic review and meta-analysis
title_full Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: A systematic review and meta-analysis
title_fullStr Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: A systematic review and meta-analysis
title_full_unstemmed Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: A systematic review and meta-analysis
title_short Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: A systematic review and meta-analysis
title_sort prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: a systematic review and meta-analysis
topic 3400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004711/
https://www.ncbi.nlm.nih.gov/pubmed/32000440
http://dx.doi.org/10.1097/MD.0000000000019000
work_keys_str_mv AT chenhailong preventionofvenousthromboembolisminpatientswithcancerwithdirectoralanticoagulantsasystematicreviewandmetaanalysis
AT taorui preventionofvenousthromboembolisminpatientswithcancerwithdirectoralanticoagulantsasystematicreviewandmetaanalysis
AT zhaohui preventionofvenousthromboembolisminpatientswithcancerwithdirectoralanticoagulantsasystematicreviewandmetaanalysis
AT jiangjianjun preventionofvenousthromboembolisminpatientswithcancerwithdirectoralanticoagulantsasystematicreviewandmetaanalysis
AT yangjin preventionofvenousthromboembolisminpatientswithcancerwithdirectoralanticoagulantsasystematicreviewandmetaanalysis